Madrigal Pharmaceuticals, Inc. Earnings logo

MDGL

Madrigal Pharmaceuticals, Inc. Earnings

$286.06

Earnings Summary

Revenue
$137.25Mn
Net Profits
$-73.24Mn
Net Profit Margins
-53.36%
Highlights
Revenue:

Madrigal Pharmaceuticals, Inc.’s revenue jumped +Inf% since last year same period to $137.25Mn in the Q1 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 32.84% jump in its revenue since last 3-months.

Net Profits:

Madrigal Pharmaceuticals, Inc.’s net profit jumped 50.36% since last year same period to $-73.24Mn in the Q1 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated -23.26% fall in its net profits since last 3-months.

Net Profit Margins:

Madrigal Pharmaceuticals, Inc.’s net profit margin jumped NaN% since last year same period to -53.36% in the Q1 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 7.21% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Madrigal Pharmaceuticals, Inc. post its latest quarter earnings
EPS Estimate Current Quarter
-6.28
EPS Estimate Current Year
-6.28
Highlights
EPS Estimate Current Quarter:

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -6.28 - a -52.26% fall from last quarter’s estimates.

EPS Estimate Current Year:

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -6.28.

Key Ratios

Key ratios of the Madrigal Pharmaceuticals, Inc. post its Q1 2025 earnings
Earning Per Share (EPS)
-3.32
Return on Assets (ROA)
-0.26
Return on Equity (ROE)
-0.5
Highlights
Earning Per Share (EPS):

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) jumped 55.01% since last year same period to -3.32 in the Q1 2025. This indicates that the Madrigal Pharmaceuticals, Inc. has generated 55.01% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Madrigal Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.26.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Madrigal Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.5.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2025-05-01
-6.28
-3.32
47.13%